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Caron A. Jacobson,1 Amin T. Turki,1 Sean M. McDonough,1 Kristen E. Stevenson,2
Haesook T. Kim,2 Grace Kao,3 Maria I. Herrera,1 Carol G. Reynolds,1
Edwin P. Alyea,1 Vincent T. Ho,1 John Koreth,1 Philippe Armand,1 Yi-Bin Chen,4 Karen Ballen,4
Robert J. Soiffer,1 Joseph H. Antin,1 Corey S. Cutler,1 Jerome Ritz1Double umbilical cord blood (DUCB) transplantation is an accepted transplantation strategy for patients
without suitable human leukocyte antigen (HLA) matched donors. However, DUCB transplantation is
associated with increased morbidity and mortality because of slow recovery of immunity and a high risk
of infection. To define the differences in immune reconstitution between DUCB transplantation and HLA
matched unrelated donor (MUD) transplantation, we performed a detailed, prospective analysis of immune
reconstitution in 42 DUCB recipients and 102 filgrastim-mobilized unrelated peripheral blood stem cell
recipients. Reconstitution of CD3 T cells was significantly delayed in the DUCB cohort compared with
the MUD cohort for 1 to 6 months posttransplantation (P\.001), including naive (CD45RO2) and memory
(CD45RO1) CD4 T cells, regulatory (CD4CD25) T cells, and CD8 T cells. In contrast, CD19 B cells recov-
eredmore rapidly in theDUCB cohort and numbers remained significantly greater from 3 to 24months after
transplantation (P5 .001). CD56CD16 natural killer (NK) cells also recovered more rapidly in DUCB recip-
ients and remained significantly greater from 1 to 24 months after transplantation. B cell activating factor
(BAFF) levels were higher in the DUCB cohort at 1 month (P\ .001), were similar in both cohorts at
3 and 6 months, and were lower in the DUCB cohort at 12 months (P 5 .002). BAFF/CD19 B cell ratios
were lower in the DUCB cohort at 3 (P5 .045), 6 (P5 .02), and 12 months (P5 .002) after transplantation.
DUCB recipients had more infections within the first 100 days after transplantation (P\.001), and there
was less chronic graft-versus-host disease (P\.001), but there were no differences in cumulative incidence
of relapse, nonrelapse death, progression-free survival, or overall survival between the 2 groups. These
results suggest that increased risk of infections is specifically associated with delayed reconstitution of all ma-
jor T cell subsets, but the increased risk is limited to the first 3 months after DUCB transplantation. There is
no increased risk of relapse, suggesting that graft-versus-leukemia activity is maintained. Early reconstitution
of B cells and NK cells may, in part, account for these findings.
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Umbilical cord blood (UCB) stem cells are
frequently used for patients with hematologic malig-
nancies who need allogeneic stem cell transplantation
but do not have human leukocyte antigen (HLA)
matched donors. Although UCB stem cells are
partially HLA mismatched, several studies have
documented that the incidence of acute and chronic
graft-versus-host disease (aGVHD, cGVHD) are not
increased compared with transplantation of HLA
matched stem cells obtained from either bone marrow
or filgrastim-mobilized peripheral blood from unre-
lated donors [1,2]. Nevertheless, a major limitation to565
Table 1. Clinical Characteristics of Patient Cohorts
DUCBT MUD P Value
N 42 102
Median age (range) 49 (20, 67) 56 (20, 73) .005
Female sex (%) 20 (48) 39 (38) .35
Conditioning regimen (reduced intensity)
Bu/Flu ± other (%) 0 (0) 102 (100) —
Melphalan/Flu/ATG ± other (%) 42 (100) 0 (0)
GVHD prophylaxis
Siro/MTX/Tac (%) 0 (0) 84 (82) —
Siro/Tac (%) 29 (69) 11 (11)
MTX/Tac (%) 0 (0) 6 (6)
Siro/MMF (%) 0 (0) 1 (<1)
Cyclosporine containing (%) 13 (31) 0 (0)
Disease
AML (%) 13 (31) 19 (19) —
ALL (%) 2 (5) 3 (3)
CML (%) 1 (2) 3 (3)
CLL/SLL/PLL (%) 2 (5) 13 (13)
MDS (%) 4 (10) 20 (20)
NHL (%) 13 (31) 16 (16)
HL (%) 5 (12) 15 (15)
MPD (%) 1 (2) 5 (5)
MM (%) 0 (0) 3 (3)
Anemia (%) 1 (2) 5 (5)
Good prognosis (%)* 14 (33) 18 (18) .05
Bu indicates busulfan; Flu, fludarabine; Siro, sirolimus; MTX, methotrex-
ate; Tac, tacrolimus; AML, acute myelogenous leukemia; ALL, acute
lymphocytic leukemia; CML, chronic myelogenous leukemia; CLL,
chronic lymphocytic leukemia; SLL, small lymphocytic leukemia; PLL,
prolymphocytic leukemia; MDS, myelodysplastic syndrome; NHL,
non-Hodgkin lymphoma; HL, Hodgkin’s lymphoma; MPD, myeloprolifer-
ative disorder; MM, multiple myeloma.
*Patients with AML or ALL in first remission or CML in chronic phase.
Also includes patients with MDS with refractory anemia (RA) or refrac-
tory anemia and ring sideroblasts (RARS).
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small number of hematopoietic stem cells (HSCs) in
these products, which results in delayed and often
inadequate myeloid and lymphoid reconstitution
[3-5]. This results in increased risk of life-threatening
infection among UCB recipients. Because total nucle-
ated cell dose and CD341 cell dose are predictive of
neutrophil and platelet engraftment, many UCB prod-
ucts are not suitable for adult recipients, and some
centers limit the use of UCB transplants to pediatric
patients [5]. One strategy that has been adopted to
overcome this limitation is the transplantation of
multiple UCB units to single recipients [6,7].
Although prospective comparative studies have not
been reported, double UCB (DUCB) transplantation
in adult patients has been shown to decrease time
to neutrophil and platelet engraftment, when
compared with historical controls [7,8]. Importantly,
transplantation with 2 partially HLA mismatched
UCB products has not generally been associated with
increased risk of aGVHD or cGVHD [7,9].
Previous studies have shown that T cell recovery is
often delayed following single-unit UCB transplanta-
tion [8,10,11]. Impaired thymic generation of T cells
resulting in relative deficiency of naive T cells
following UCB transplantation has also been reported
[12]. Survival is improved in UCB transplant patients
with better restoration of thymic function and higher
ratios of na€ıve to memory T cells [12,13]. In contrast,
B cells and natural killer (NK) cells appear to recover
quickly after UCB transplantation [14]. UCB also
contains relatively more CD4CD25 T regulatory cells
(Treg) that may have more potent suppressor function
than those in adult peripheral blood [15].
To define the immunologic effects of transplanta-
tion with 2 unrelated partially HLA mismatched
UCB units in adults, we undertook a detailed prospec-
tive assessment of immune reconstitution in a cohort of
42 patients who underwent allogeneic transplantation
at the Dana-Farber/Harvard Cancer Center between
2003 and 2008. To clarify the extent to which immune
reconstitution was delayed after transplantation of
2 UCB products, results were compared with a cohort
of 102 adults who received filgrastim-mobilized pe-
ripheral blood stem cells from HLA-matched
unrelated donors.MATERIALS AND METHODS
Patients
Two cohorts of patients with hematologic
malignancies who underwent allogeneic hematopoietic
stem cell transplantation (HSCT) at the Dana-Farber/
Harvard Cancer Center were included in this study.
Cohort 1 (42 patients) received 2 partially HLA
mismatched unrelated umbilical cord blood productsbetween December 2003 and January 2008. Cohort
2 (102patients) receivedfilgrastimmobilizedperipheral
blood stem cells from HLA matched unrelated donors
between January 2005 and February 2009. All patients
received reduced-intensity conditioning (RIC).
Patients who died or relapsed before day 100 were
excluded from this analysis. Clinical characteristics of
both groups are summarized in Table 1. A third cohort
of 30 healthy adults was also included for comparison.
Patient samples for analysis of immune reconstitution
were generally obtained at 1, 3, 6, 9, 12, 18, and
24 months after transplantation. All samples were
collected after written informed consent was obtained
in accordance with the Declaration of Helsinki and
approved by the Human Subjects Protection Commit-
tee of the Dana-Farber/Harvard Cancer Center.
Flow Cytometry Analysis of Peripheral Blood
Cells
Flow cytometry was performed by 1 of 2 methods.
In the first, accounting for 47% of samples, freshly col-
lected whole blood in EDTA was analyzed using
a Multitest 6 color TBNK reagent panel of monoclo-
nal antibodies specific for CD3 (FITC), CD16 (PE),
CD45 (PerCP-cy5.5), CD4 (PE-Cy7), CD19 (APC),
and CD8 (APC-Cy7). Whole blood was processed
Table 2. Clinical Outcomes of Patient Cohorts
DUCBT MUD P Value
N 42 102
Acute GVHD grade II-IV (%) 9 (21) 12 (12) .19
Chronic GVHD (%) 10 (24) 55 (54) <.001
2-year PFS (95% CI) 49% (32,64) 57% (44,68) .88
2-year OS (95% CI) 66% (49,79) 68% (54,79) .93
2-year NRM (95% CI) 11% (3,23) 11% (4,20) .63
2-year relapse (95% CI) 40% (25,55) 32% (22,43) .87
Infection <100 days
Overall 25 (59) 9 (8) <.001
Bacterial 21 (50) 8 (8) <.001
Viral 12 (29) 1 (1) <.001
Fungal 2 (5) 0 (0) .08
Infection rate overall (%) 29 (69) 34 (33) <.001
Time to engraftment (days)
Neutrophil 21.5 (13-107) N/A N/A
Platelet 41.5 (16-162) N/A N/A
CI indicates confidence interval; NRM, nonrelapse mortality.
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(BD Biosciences, San Jose, CA). Red blood cells were
lysed using a FACS lysis solution, and leukocytes
were fixed before analysis. Cells were analyzed using
a FACSCanto II instrument and analysis software
(BD Biosciences). The lymphocyte gate was estab-
lished using forward and side scatter. A minimum of
50,000 lymphocytes were analyzed to ensure adequate
subset analysis.
In the second method, accounting for 53% of
samples, freshly collected whole blood in EDTA was
analyzed by flow cytometry using a 5- or 7-reagent
panel of fluorochrome-conjugated monoclonal anti-
bodies specific for the following surface antigens:
CD3, CD4, CD5, CD11c, CD14, CD16, CD19,
CD25, CD27, CD45, CD45RO, CD56, CD62L,
CD86, CD127, HLA-DR, NKG2D (BD Biosciences);
CD3, CD8, CD14, CD20, CD56 (Beckman Coulter,
Fullerton, CA); BAFF-R (eBioscience, San Diego,
CA); and CD123 (Miltenyi, Bergisch Gladbach,
Germany). Reagents were divided into 4 or 6 tubes.
After incubationwithmonoclonal antibodies, red blood
cell lysis was performed using either BDPharmLyse or
an automated TQ Prep workstation (Beckman
Coulter). Flow cytometry was performed on a FACS-
Canto II (BD Bioscience) and analyzed using BD
FACSDiva software, or on a Beckman Coulter
FC500, with Beckman Coulter CXP analysis software.
Serum Immunoglobulin Levels
Immunoglobulin levels were assessed by standard
clinical laboratory methods. IgG, IgA, and IgM assays
were performed with a nephelometer.
B Cell Activating Factor (BAFF) Levels
Soluble BAFF in patient plasma samples was
measured using a commercially available enzyme-
linked immunosorbent assay (ELISA) and the manu-
facturer’s recommended procedures (R&D Systems,
Minneapolis, MN).
Statistical Analysis
Patient baseline and transplant characteristics,
infection rate, and GVHD rate were reported descrip-
tively, and compared using the Fisher exact test or
Wilcoxon rank sum test. Immunologic reconstitution
data, BAFF, BAFF/B cell ratio data were analyzed
descriptively at each time point and compared using
the Wilcoxon rank sum test. All P values are 2 sided
at the significance level of .05, and multiple compari-
sons were not adjusted for.
Kaplan-Meier curves for overall survival (OS) and
progression-free survival (PFS) were constructed for
each group and compared using the log-rank test. OS
was calculated from the date of transplantation to the
date of death. PFS was calculated from the date oftransplantation to the time of relapse or death, which-
ever occurred first. Patients not experiencing any event
(relapse or death) were censored at the date last known
alive and relapse-free. Cumulative incidence curves for
nonrelapse death and progression or relapse with or
without death were constructed, reflecting time to
progression and time to nonrelapse death as competing
risks.Time to progression and time to nonrelapse death
were measured from the date of stem cell infusion. The
difference between cumulative incidence curves in the
presence of a competing risk was tested using the
Gray method [16]. All calculations were performed
using SAS 9.2 (SAS Institute, Cary, NC) and R 2.10.1.
Time to neutrophil engraftment was designated as
the first of 3 consecutive days with an absolute neutro-
phil count .500/mL. Time to platelet engraftment
was defined as the first of 7 consecutive days on which
the platelet count was at least 20,000/mL. Standard
criteria were used to define fever, blood stream
infections, and other infectious disease syndromes
[17-19]. Infections were defined and classified
either by recovery of microorganisms or by clinical
documentation when microorganisms were not
recovered. Viral infections were defined by increasing
viral load in serial measurements that prompted the
clinician to initiate treatment.RESULTS
Clinical Characteristics of Patient Groups
A total of 144 patients were included in this study;
42 underwent a DUCB (cohort 1) from a partially
HLA mismatched unrelated donor; 102 underwent
an HLA matched adult, unrelated donor transplanta-
tion (MUD; cohort 2). Clinical characteristics and
outcomes for each cohort are summarized in Tables 1
and 2, respectively.
The conditioning regimen for the DUCB cohort
included melphalan, fludarabine, and thymoglobulin
Figure 1. Reconstitution of CD3, CD4, and CD8 T cells after stem cell transplantation. Median absolute CD3 (A), CD4 (B), and CD8 (C) T cells/mL at
1, 2, 3, 6, 9, 12, 18, and 24 months after DUCB (blue lines) and MUD (pink lines) transplantation. The sample sizes at each time point are 26 versus 81,
27 versus 88, 33 versus 77, 35 versus 65, 20 versus 54, 31 versus 52, 11 versus 34, and 14 versus 23, for DUCB andMUD cohorts, respectively. The range
of absolute CD3, CD4, and CD8 T cell counts in our normal healthy control cohort is represented in gray. *Indicates differences that are statistically
significant (P\.05).
568 Biol Blood Marrow Transplant 18:565-574, 2012C. A. Jacobson et al.(ATG) in all patients. The median total cell dose
was 0.42  108 nucleated cells/kg and 0.28  106
CD341 cells/kg. GVHD prophylaxis consisted of
sirolimus plus tacrolimus in 69% of patients; all other
patients received cyclosporine-based regimens.
Patients in the MUD cohort received significantly
greater numbers ofHSCs, with amedian total cell dose
of 11.47  108 nucleated cells/kg and 9.31  106
CD341 cells/kg. Conditioning was reduced intensity
and included busulfan and fludarabine in all patients
[7]. GVHD prophylaxis included sirolimus and tacro-
limus for 93% of patients; 82% of patients also
received methotrexate.
The underlying malignant diseases of the 2 groups
were generally similar. However, the DUCB cohort
had a significantly higher percentage of patients with
favorable disease prognosis (P 5 .05), and the median
age of the MUD cohort was significantly older
(P5 .005). Both cohorts had a relatively low incidence
of aGVHD (\25%), but the MUD group had a signif-
icantly greater incidence of cGVHD than the DUCB
group (54% versus 24%, respectively, P \ .001).
Two-year PFS and OS were not different between
the 2 groups (49% versus 57%, P 5 .88; 66% versus
68%, P 5 .93, respectively). There was a significantly
higher overall rate of infection, especially in the first
100 days after transplantation, in the DUCB cohortcompared with the MUD cohort (69% versus 33%,
P \ .001 for overall infection; 59% versus 8%,
P\ .001 for the first 100 day after transplantation in-
fection). Specifically, viral and bacterial infection rates
were higher in the DUCB cohort in the first 100 days
after transplantation (29% versus 1%, P \ .001;
50% versus 8%, P\ .001), whereas the incidence of
fungal infections was low in both cohorts. The median
time to neutrophil and platelet engraftment was
21.5 (13-107) and 41.5 (16-162) days, respectively,
for patients following DUCB. Although both groups
received RIC, the regimen used in the MUD cohort
was less intensive, and many patients in this group
did not experience a neutrophil or platelet count nadir.
Reconstitution of T Cells
Reconstitution of CD3 T cells was significantly
delayed in recipients of DUCB compared with
MUD, for at least 6 months after transplantation
(P\ .001) (Figure 1A). By 12 months after transplan-
tation, there was no longer a significant difference
between these cohorts, and by 24 months, the median
number of CD3T cells in the DUCB cohort surpassed
that in the MUD cohort (1073 cells/mL versus
804 cells/mL, P 5 .21). These values fell within the
normal range of absolute CD3 T cells for our healthy
adult control population (572-2090 cells/mL).
Figure 2. Reconstitution of CD19 and CD20 B cells after stem cell transplantation. Median absolute CD19 B cells/mL (A), and CD56CD16NK cells/mL
(B) at 1, 2, 3, 6, 9, 12, 18, and 24 months after DUCB (blue lines) and MUD (pink lines) transplantation. The sample sizes at each time point are 27 versus
80, 27 versus 88, 33 versus 77, 35 versus 64, 20 versus 54, 31 versus 53, 11 versus 34, and 14 versus 23, for DUCB and MUD cohorts, respectively. The
range of absolute CD19 B cell and CD56CD16NK cell counts in our normal healthy control cohort is represented in gray. *Indicates differences that are
statistically significant (P\.05).
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DUCB cohort for at least 6 months following
transplantation (P \ .001) (Figure 1B). The median
number of CD4 T cells in this cohort did not reach
.200 cells/mL until 9 months after transplantation and
did not reach normal levels until 2 years after transplan-
tation. However, by 12 months, CD4 T cell recovery
was similar in both cohorts. Reconstitution of CD8
T cells was likewise delayed in DUCB patients
(Figure 1C). Although this difference was statistically
significant for at least 6months following transplantation
(P\ .001), themagnitude of this difference was less than
for CD4 T cells, and patients in both cohorts reached
anormalCD8Tcell count, as determinedbyourhealthy
adult cohort, in the first year after transplantation.
B Cell and NK Cell Recovery
In contrast to T lymphocytes, CD19 B cell recov-
ery was more rapid in the DUCB cohort (Figure 2A).
Absolute numbers of CD19 B cells reached a nadir in
both cohorts by 1 month after transplantation, but
by 3 months after transplantation, median B cell num-
bers were significantly greater in the DUCB cohort
than in the MUD cohort (176 cells/mL versus
21 cells/mL, P 5 .001), and this difference persisted
and intensified over the ensuing 21 month follow-up
period. Although not shown, similar results were
observed if CD20 was used to track B cell recovery.
Remarkably, by 12 months after transplantation,
median CD19 B cell numbers in the DUCB cohort
recovered to levels that were higher than our healthy
adult population.
Unlike the T cell and B cell populations,
CD56CD16 NK cells did not fall following transplan-
tation and instead increased steadily in both cohorts
(Figure 2B). The median number of NK cells in theDUCB cohort remained significantly higher than
those in the MUD cohort throughout the entire
24 month follow-up period.
Reconstitution of T Cell Subsets
Differences in the proportion of na€ıve andmemory
T cells following UCB and conventional allogeneic
stem cell transplantation have been reported previ-
ously [20]. We examined this in our patient cohorts
using CD45RO to differentiate na€ıve from memory
CD4 T cells (naive 5 CD4CD45RO2, memory 5
CD4CD45RO1). There were significantly fewer
CD4CD45RO2 naive T cells following DUCB com-
pared with MUD, both in absolute numbers and rela-
tive proportions, which persisted for at least 6 months
following transplantation (Figure 3A). A similar
pattern was observed for CD4CD45RO1 memory
T cells in both populations, except that memory
CD4 T cells began to recover between 3 and 6 months
after transplantation in the DUCB cohort (Figure 3B).
CD4CD25 Treg numbers were significantly lower
in the DUCB compared with the MUD cohort in the
first 6 months after transplantation (P # .004)
(Figure 3C). After this early period, there was no sig-
nificant difference in absolute Treg numbers between
the 2 cohorts. Compared with our healthy adult
control cohort, DUCB and MUD patients had lower
median Treg numbers throughout the first year after
transplantation. Normal levels of Treg were not
reached until 18 to 24 months after transplantation.
Finally, cells that express both NK and T cell
markers (CD3CD56) were significantly lower in the
DUCB cohort compared with the MUD cohort
from 1 month after transplantation throughout the
24-month follow-up period (Figure 3D). In DUCB
patients, the median number of cells with this unique
Figure 3. Reconstitution of T cell subsets after stem cell transplantation. Median absolute CD4CD45RO2 naive (A), CD4CD45RO1memory (B), and
CD4CD25 regulatory (C) T cells/mL, and CD3CD56 cells/mL (D) at 1, 2, 3, 6, 9, 12, 18, and 24 months after DUCB (blue lines) and MUD (pink lines)
transplantation. The sample sizes at each time point are 21 versus 79, 20 versus 88, 22 versus 77, 24 versus 64, 3 versus 53, 17 versus 52, 3 versus 34, and
6 versus 23, for DUCB and MUD cohorts, respectively. The range of absolute na€ıve, memory, and regulatory T cells and CD3CD56 cells in our normal
healthy control cohort is represented in gray. *Indicates differences that are statistically significant (P\.05).
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adult cohort throughout this period.
Dendritic Cell (DC) Subsets
Myeloid and plasmacytoid DCs can be distin-
guished by expression of CD11c and CD123, respec-
tively. When our 2 cohorts were analyzed for CD11c1
myeloid DCs, there was no statistically significant dif-
ference at any time point (Figure 4A). Plasmacytoid
DCs, however, were higher in the DUCB cohort com-
pared with the MUD cohort at 12 months (P 5 .005);
this difference resolved by 24 months (Figure 4B).
Immunoglobulin Levels
To assess the functionality of the B cell compart-
ment following DUCB transplantation, serum immu-
noglobulin levels were measured for up to 12 months
(Figure 5). IgG levels in both groups of patients grad-
ually fell following transplantation. In the DUCB
cohort, IgG levels began to recover between 5 and
6 months after transplantation and recovered to nor-
mal levels (Figure 5). In contrast, IgG levels continued
to fall in the MUD cohort and remained below normal
at 12 months. IgG infusions did not account for this
difference because patients who received IgG infusions
failed to reach normal IgG levels postinfusion (data
not shown). IgM levels were below normal in both
cohorts for the first 3 months following transplanta-
tion and recovered more quickly to normal levels by
4 and 6 months in the DUCB and MUD cohorts,respectively (data not shown). IgA levels did not reach
normal levels throughout the 12 month follow-up
period for the DUCB cohort, and fell to below normal
levels by 4 to 6 months after transplantation for the
MUD cohort (data not shown).
BAFF and BAFF/B Cell Ratios
At 1month after transplantation, BAFF levels were
significantly higher in the DUCB cohort compared
with the MUD cohort (median 25.47 versus 11.43,
P\ .001), but BAFF/CD19 B cell ratios were similar
(P 5 .11) (Figure 6A and B). BAFF levels gradually
fell in the DUCB cohort and returned to normal levels
12 months after transplantation. In contrast, BAFF
levels remained elevated in the MUD cohort. Consid-
ering the rapid recovery of CD19 B cells in the DUCB
cohort, the BAFF/CD19 B cell ratio normalized in
these patients by 12 months but remained significantly
elevated in the MUD group at 12 months after
transplantation (Figure 6B).
Posttransplantation Lymphoproliferative
Disorder (PTLD) and Mixed Chimerism
Following DUCB transplantation, patients are at
increased risk of developing PTLD because of expan-
sion of Epstein-Barr virus–infected host B cells in the
absence of Epstein-Barr virus immunity in the graft.
In our DUCB cohort, there were 4 cases of PTLD,
whereas there were no cases in the MUD cohort.
Comparing the immune reconstitution of patients
Figure 4. Reconstitution of myeloid and plasmacytoid dendritic cells after stem cell transplantation. Absolute and median absolute CD11c myeloid (A)
and CD123 plasmacytoid (B) dendritic cells/mL at 6 and 12 months after DUCB (blue diamonds) and MUD (pink circles) transplantation. The sample
sizes at each time point are 6 versus 31, and 9 versus 26 for DUCB and MUD cohorts, respectively. *Indicates differences that are statistically
significant (P\.05).
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without PTLD did not reveal significant differences,
although the number of cases of PTLD was small.
Sixty-seven percent of DUCB patients achieved
.90% chimerism of a dominant cord by 3 months
after transplantation and 33% had persistent engraft-
ment of HSCs from both umbilical cord products.
We examined patterns of immune reconstitution in
these patients but observed no significant differences
in patients with an early dominant cord compared
with patients with persistent mixed chimerism (data
not shown).DISCUSSION
The primary objective of this study was to define
patterns of immune reconstitution in adult patientsFigure 5. Immunoglobulin levels after stem cell transplantation.
Median serum IgG levels in mg/dL at 1-month intervals after transplan-
tation from 1 month to 1 year after DUCB (blue line) and MUD (pink
line) transplantation. The sample sizes at each 1-month time point are
50 versus 113, 44 versus 106, 32 versus 87, 44 versus 61, 36 versus
75, 36 versus 60, 34 versus 55, 27 versus 56, 22 versus 53, 18 versus
52, 23 versus 53, and 14 versus 49 for DUCB and MUD cohorts, respec-
tively. The range of normal IgG levels is represented in gray.who receive UCB stem cells from 2 partially HLAmis-
matched donors. To determine the magnitude of
delayed recovery, immune reconstitution was com-
pared with a cohort of 102 adult patients who received
filgrastim-mobilized peripheral blood stem cells from
HLA matched unrelated donors. Both cohorts
received RIC before transplantation, but MUD recip-
ients received 33-fold greater numbers of CD341
HSCs and did not receive ATG as part of the condi-
tioning regimen. With this large difference in stem
cell dose and important difference in conditioning,
there was a significant delay in T cell recovery across
all T cell subtypes. Nevertheless, B cell and NK cell
recovery occurred earlier in DUCB recipients. B cell
recovery was both quantitative and qualitative, as
recovery of IgG and IgM levels paralleled B cell recov-
ery. Despite this, delayed T cell recovery appears to be
associated with an increased rate of infection in the
first 100 days following DUCB transplantation.
Although UCB contains relatively few memory
T cells, early T cell reconstitution followingUCB trans-
plantation is accomplished primarily through thymus-
independent peripheral expansion of mature donor
T cells [20,21,22]. The inclusion of pretransplantation
ATG in conditioning to enhance immune suppression
of the recipient and prevent rejection of HLA
mismatched stem cells also further depleted donor
T cells in the early posttransplantation period. As
a result, T cell recovery was significantly delayed, and
DUCB patients had very few circulating T cells during
the first 3 months after transplantation. CD4 T cell
counts began to increase 3 months after
transplantation, and this was due primarily to
expansion of CD4 memory T cells; CD4 naive T cell
and CD8 T cell numbers in peripheral blood remained
Figure 6. Levels of BAFF and BAFF/CD19 B cells after stem cell transplantation. Median levels of BAFF in ng/mL (A), and BAFF/CD19 B cells (B) at 1, 3,
6, and 12 months after DUCB (blue lines) and MUD (pink lines) transplantation. The sample sizes at each time point are 22 versus 77, 30 versus 71, 21
versus 59, and 25 versus 37 for DUCB and MUD cohorts, respectively. The range of normal BAFF and BAFF/CD19 B cell ratios are represented in gray
[24]. *Indicates differences that are statistically significant (P\.05).
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However, despite the very delayed recovery of naive
CD4 T cells and CD8 T cells, the period of increased
risk of infections appeared to be restricted to the first
100 days after transplantation. This suggests that the
recovery of memory CD4 T cells that began to occur
at this time, along with rapid recovery of B and NK
cells, was sufficient to reduce the risk of opportunistic
infections in the DUCB cohort.
Our analysis of T cell subsets indicated that
recovery of naive CD4 T cells was more delayed in
DUCB patients than any other subset. Very few
CD4CD45RO2 naive T cells were present in periph-
eral blood for at least 6 months after transplantation.
Unlike memory T cells that can undergo extensive
peripheral expansion, recovery of naive CD4 T cells
is dependent on the differentiation of hematopoietic
progenitor cells and subsequent maturation in the thy-
mic microenvironment. Although reduced in number,
naive CD4T cells were readily detectable in peripheral
blood 1 month after transplantation in our MUD
cohort. This comparison suggests that thymopoiesis
can recover relatively soon after RIC. Consequently,
the prolonged delay in recovery of naive T cells was
most likely because of the relatively low number of
HSCs transplanted in the DUCB cohort. Although
we are not able to directly compare reconstitution
with 1 or 2 UCB products, it does not appear that
the infusion of 2 UCB units enhanced T cell recovery
after transplantation. In part, this may reflect the rapid
conversion to single cord hematopoiesis in 67% of
patients. This further limits the pool ofHSCs available
for T cell reconstitution in the DUCB cohort.
In contrast to T cells, B cells and NK cells recov-
ered more rapidly in DUCB patients. The reasons
for this are unknown but may reflect the more severe
lymphopenia that occurs in the DUCB cohort. Both
the use of ATG in the conditioning regimen and thelower number of mature lymphoid cells in DUCB
products likely contributed to more severe and pro-
longed lymphopenia in these patients. Lymphocyte re-
covery in response to lymphopenia is mediated
primarily by homeostatic cytokines such as IL-7,
IL-15, and BAFF [12,23]. BAFF has been shown to
play a critical role in B cell recovery following
myeloablation [24]. BAFF is a member of the tumor
necrosis factor family and under normal conditions
promotes the survival of nonautoreactive transitional
B cells [25]. BAFF levels were significantly higher
1 month following transplantation in the DUCB co-
hort; by 3 months, this difference disappeared, coinci-
dent with the rapid recovery of B cells.
A closer examination of T cell subsets revealed sig-
nificant delay in recovery of CD4CD25 Tregs. De-
spite studies showing that cord blood CD4CD25
Tregs are relatively more abundant, and havemore po-
tent suppressor function than their peripheral blood-
derived counterparts, Treg recovery was delayed for
the first 6 months following DUCB transplantation
in our study [15,26,27]. Recent studies in patients
who receive myeloablative conditioning have shown
that reconstitution of Tregs after transplantation is
primarily because of extensive proliferation and
expansion of memory Tregs [28]. In the current study,
recovery of Tregs closely mirrored the recovery of
CD4CD45RO1 memory T cells in both DUCB and
MUD cohorts. However, the delay in Treg reconstitu-
tion in DUCB patients was not associated with an in-
creased incidence of GVHD, presumably because
this is not a selective deficiency and recovery of effector
T cells is also delayed in these patients. The role of
CD3CD56 cells in immune reconstitution after
allogeneic stem cell transplantation has not been pre-
viously defined. These cells exhibit NK cell cytolytic
functions but also express CD3 and abT cell receptors
[29]. Although conventional NK cells recovered
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CD3CD56 cells was markedly delayed. This likely
reflects the very low frequency of mature cells with
this phenotype in cord blood allografts, but other
factors may also contribute to the delayed reconstitu-
tion of these cells [30].
Last, the 2 groups differed with respect to plasma-
cytoid (CD123) but not myeloid (CD11c) DC recon-
stitution, with the former being higher in the DUCB
cohort 12 months after transplantation. This is consis-
tent with the known proportion of plasmacytoid and
myeloid DCs in cord blood, compared with peripheral
blood stem cell allografts [31]. Cord blood–derived
DCs are phenotypically different from their peripheral
blood counterparts in that they are immature, poor
stimulators of allogeneic T cells in vitro, and result
in a Th2 bias [31]. The differences in the relative pro-
portion of DC subtypes, and the phenotype of DCs, in
a cord blood allograft may also contribute to the lower
rates of GVHD following DUCB transplantation.
Consistent with the other reports, we observed
a significantly lower rate of cGVHD following
DUCB transplantation, even though all UCB units
were partially HLA mismatched (Chen et al., in sub-
mission). There are a number of potential explanations
for the difference in GVHD, some of which can be
attributable to the differences in immune reconstitu-
tion reported here. As noted previously, recovery of
donor T cells was significantly delayed in the DUCB
cohort. The early reconstitution of NK cells and
B cells, and the subsequent normalization of BAFF and
BAFF/B cell ratios following DUCB transplantation,
may also contribute to a lower incidence of cGVHD.
Studies in murine models have suggested that NK cells
may play an immune regulatory role through their
ability to recognize and lyse alloreactive T cells [32].
Additionally, in the setting of B cell lymphopenia,
excess BAFF levels have been shown to promote the
survival of autoreactive B cells [33]. Elevated BAFF
levels have been documented in various autoimmune
conditions, as well as in patients with cGVHD [34].
In this latter group, prolonged elevation of BAFF/B
cell ratio was specifically associated with active disease,
whereas patients with treatment-responsive or no
history of cGVHD had BAFF levels that gradually
normalized with rising B cell numbers [34,35]. The
pattern of B cell recovery associated with the
development of cGVHD was clearly evident in our
MUD cohort. In contrast, BAFF levels and BAFF/B
cell ratios rapidly normalized as B cells recovered in
our DUCB patients and this was associated with
a low incidence of cGVHD.
Although delayed T cell reconstitution was associ-
ated with increased incidence of infections in DUCB
patients, there was no difference in relapse rate, PFS,
or OS. Although the patients all survived past day
100 post-HSCT, a larger analysis comparing RICDUCBT to RIC MUD HSCT including all patients
has confirmed these clinical findings (Chen et al., in
submission). These results suggest that graft-versus-
leukemia activity was maintained despite delayed
T cell reconstitution. Further studies are needed to
define the mechanisms responsible for graft-versus-
leukemia in this setting, but the rapid recovery of
donor B cells as well as NK cells may play an
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